While genomic profiling of patient tumors has become commonplace, clinically actionable biomarkers for gastric cancer treatment are limited to HER2 positivity/amplification, microsatellite instability-high (MSI-H) status, and PD-L1 overexpression. This evidence concerns the gene ERBB2 and gastric cancer.